R&D | May 25, 2026
AstraZeneca to showcase cancer pipeline push at ASCO 2026
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Access to genomic testing, not therapy cost, is the biggest challenge
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Complex tumour removed in a young patient without major pancreatic loss, reducing risk of lifelong diabetes
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Move to accelerate cancer care expansion across India
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
